TargetMol

Nilvadipine

Product Code:
 
TAR-T1422
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1422-10mg10mg£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1422-1mL1 mL * 10 mM (in DMSO)£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1422-50mg50mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1422-100mg100mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1422-200mg200mg£180.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1422-500mg500mg£360.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Nilvadipine, a calcium channel blocker (CCB), is utilized for treatment of hypertension.
CAS:
75530-68-6
Formula:
C19H19N3O6
Molecular Weight:
385.376
Pathway:
Membrane transporter/Ion channel; Metabolism
Purity:
0.9978
SMILES:
COC(=O)C1=C(NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N
Target:
Calcium Channel

References

1. Nomoto A, et al. Atherosclerosis, 1988, 72(2-3), 213-219. 2. Ozawa Y, et al. J Cardiovasc Pharmacol, 1999, 33(2), 243-247. 3. Yamazaki H, et al. Invest Ophthalmol Vis Sci, 2002, 43(4), 919-926. 4. Paris D, et al. Brain Res, 2004, 1999(1), 53-61. 5. Oyanagui Y, et al. Arzneimittelforschung, 1991, 41(5), 469-474.